3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
21
Phase 2
5
Phase 3
2
Phase 2/3
1
Phase 1
1
Status
Recruiting
1
Active not recruiting
1
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
2
Sponsor
Cancer Type
Genitourinary
12
Breast
11
Other hematologic neoplasm
7
Gastrointestinal
7
Thoracic
6
Lymphoid
6
Head & Neck
6
Tumor-Agnostic
2
Sarcoma
2
Other
2
Gynecologic
2
Plasma cell
1
Other solid neoplasm
1
Myeloid
1
Dermatologic
1
CNS
1
Conditions
Ovarian Neoplasms
1
Endometrial Clear Cell Adenocarcinoma
1
Interventions
Paclitaxel
150
Carboplatin
110
Cisplatin
95
Bevacizumab
42
Topotecan
39
Gemcitabine
38
liposomal doxorubicin
34
Radiotherapy
29
Doxorubicin
27
Brachytherapy
26
Taxes
24
pembrolizumab
20
olaparib
20
Drug Therapy
20
Hyperthermic Intraperitoneal Chemotherapy
16
Chemotherapy, Adjuvant
16
human papillomavirus vaccine, L1 type 16, 18
15
Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18
14
Docetaxel
13
Neoadjuvant Therapy
12
Platinum
10
niraparib
9
Radiation
9
1,2-diaminocyclohexaneplatinum II citrate
9
Vaccines, Synthetic
8
Surgical Procedures, Operative
8
atezolizumab
7
Specimen Handling
7
Papillomavirus Vaccines
7
Letrozole
7
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Phase 3
×
Standard of Care
×
Gynecologic
×
Clear all
NCT03602859
2025-12-31
FIRST
Tesaro, Inc.
Phase 3
Active not recruiting
1,400 enrolled
18 charts
NCT03422198
2025-12-12
SAVE
University of Utah
Phase 3
Recruiting
188 enrolled
15 charts